Skip to main content
CMEducation Resources ScrollCall
  • menu
  • menu
  • person
  • Search
  • Specialty
  • Cardiology chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • Diabetes chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • Specialty Program
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Cytokine Immunotherapy chevron_right
  • Hypothyroidism chevron_right
  • Specialty Program
  • Parkinson's Diseasechevron_right
  • Specialty
  • Cancer chevron_right

  • Specialty Program
  • Cytokine Immunotherapy chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Pain Management chevron_right
  • Specialty
  • Primary Care chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Parkinson's Diseasechevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • Specialty
  • Dermatology chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Specialty
  • Biologicschevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Biosimilars for RA chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • MAC Lung Disease chevron_right

  • Specialty Program
  • MAC Lung Disease chevron_right
    • close
    CMEducation Resources iQ&A
    • person
    • Home
    • Specialtieschevron_right
      • chevron_leftTopics
      • Cardiology
      • Diabetes
      • Endocrinology
      • Neurology
      • Cancer
      • Primary Care
      • Dermatology
      • Biologics
      • MAC Lung Disease
    • Submit A Question
    close

    Dr. Wong Seng Weng, MBBS, MRCP(UK), FAMS (Medical Oncology)

    Dr. Wong Seng Weng, MBBS, MRCP(UK), FAMS (Medical Oncology)

    Medical Director & Consultant Medical Oncologist 
    The Cancer Centre (Singapore Medical Group) 
    Paragon Medical & Mt Elizabeth Novena 
    Specialist Centre Visiting Consultant 
    Mt Elizabeth Hospital & Mt Elizabeth Novena Hospital 
    Adjunct Clinician Scientist 
    Institute of Bioengineering & Nanotechnology (IBN)
    Agency for Science, Technology & Research (A*STAR) 
    Singapore


    Related Videos

    What is your current guidance about whether and/or how and when to integrate tests for circulating tumor DNA (ctDNA) into protocols for precision cancer medicine? Video

    What is your current guidance about whether and/or how and when to integrate tests for circulating tumor DNA (ctDNA) into protocols for precision cancer medicine?

    What is your current guidance about whether and/or how and when to integrate tests for circulating tumor DNA (ctDNA) into protocols for precision cancer medicine?

    Can you give an example of a patient in which the failure to initially deploy, but subsequent use of NGS-based, comprehensive molecular profiling led to improvements in their clinical course? Video

    Can you give an example of a patient in which the failure to initially deploy, but subsequent use of NGS-based, comprehensive molecular profiling led to improvements in their clinical course?

    Can you give us a specific example of a patient in which the failure to initially deploy, but then subsequent use of NGS-based, comprehensive molecular profiling led to documented improvements in their clinical course based on identification of targeted agent?

    What did we learn from the SHIVA Trial and how might the "disappointing" results of this trial have been misinterpreted, thereby underestimating the potential benefits of targeted therapy? Video

    What did we learn from the SHIVA Trial and how might the "disappointing" results of this trial have been misinterpreted, thereby underestimating the potential benefits of targeted therapy?

    What did we learn from the SHIVA Trial and in what ways might the “disappointing” results of this trial have been misinterpreted, thereby underestimating the potential benefits of targeted therapy?

    When in the course of diagnosis and history does whole exome, hybrid capture NGS sequencing fit into the diagnostic roadmap for identifying targeted therapies? How does NGS compare to hot spot testing? Video

    When in the course of diagnosis and history does whole exome, hybrid capture NGS sequencing fit into the diagnostic roadmap for identifying targeted therapies? How does NGS compare to hot spot testing?

    When exactly, in the course of a patient’s cancer diagnosis and history, does whole exome, hybrid capture NGS sequencing fit into the diagnostic roadmap for the purpose of identifying targeted therapies? And how do the capabilities of ...

    What are the implications of FDA approval of PD-1 inhibitors across a broad spectrum of mismatch repair-deficient tumors? What are the implications for NGS-based molecular diagnostics? Video

    What are the implications of FDA approval of PD-1 inhibitors across a broad spectrum of mismatch repair-deficient tumors? What are the implications for NGS-based molecular diagnostics?

    What are the implications of the FDA having approved PD-1 inhibitors across a broad spectrum of mismatch repair-deficient tumors? And what are the implications for NGS-based molecular diagnostics?

    Disclaimer:
    Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
    Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
    Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
    Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

    Clinical Webcasts®

    Powered by BroadcastMedBROADCASTMED